BLACK WEEKSBočice −15% · kompleti −10% · ostalo −5%s kodomBesplatna dostava u Njemačkoj od 200 €

Ova je stranica automatski prevedena i može sadržavati pogreške. Jeste li izvorni govornik? Rado ćemo primiti vaše povratne informacije i ispravke.Pošaljite povratne informacije

The Peptide Desk The Peptide Desk
Tirzepatide, fotografija proizvoda

8 laboratorijskih izvješća

PDF
99%
Čistoća
Testirano
Tirzepatide 10mg
Laboratorij
Analiza Białek
Datum
November 2026
Rezultat
99% purity (10.88 mg measured)
Endotoksini
5.99 EU/vial
Br. narudžbe
Lozinka

Neovisno testirano, može se provjeriti lozinkom izravno u laboratoriju.

GLP-1

Tirzepatide

GLP-1

Narudžba

Jedinična cijena - Besplatna dostava u Njemačkoj iznad 200 € tijekom akcije Black Weeks
  • DHL s praćenjem
  • Diskretno pakiranje

4.6 od 5 na Trustpilotu73 recenzija

Traženo i kao: Tirzepatid · Tirze · LY3298176

Na prvi pogled

Tirzepatide u brojkama

Ključni podaci iz našeg leksikona. Povucite točku po krivulji i pogledajte koliko, prema izračunu, ostaje nakon jedne doze.

Cijeli članak u leksikonu

How long does it stay in the body?

Share left after one dose, calculated with a half-life of ~5 days

Half-life ~5 days
After 10 days: 25 %
Day 550 %Day 7, next dose38 %Day 1025 %Day 1512.5 %Day 253.1 %

Simplified model without an absorption phase, half-life from the TPD lexicon.

Half-life

~5days

Class
Dual GIP / GLP-1 agonist
Frequency
Once weeklysubcutaneous
Form
Lyophilised powderreconstituted with BAC water
Sizes
5 to 120 mg10 sizes in the shop

Znanje

Sve o Tirzepatide

Detaljne informacije uskoro.

Dobro je imati

Što vam uz to treba

Bakteriostatska voda automatski se dodaje u košaricu. Štrcaljke i maramice jednim klikom.

Inzulinske štrcaljke

10 kom. · 5.50 €

Alkoholne maramice

50 kom. · 10 €

Koliko vode?

Jedinice na štrcaljki za veličinu vaše bočice.

Otvori kalkulator →

FAQ

Česta pitanja

Izvori za svaki odgovor: članak u leksikonu

Imate još pitanja?

Pišite nam, naš tim će vam pomoći.

Is Tirzepatide approved?

Yes. The first approval came in May 2022 in the USA for type 2 diabetes, the European Medicines Agency issued a positive opinion shortly after. ChEMBL now lists type 2 diabetes, obesity and overweight as approved indications. The information here describes the state of research and is not a recommendation for use.

How does Tirzepatide differ from Semaglutide and Retatrutide?

The number of receptors. Semaglutide acts only on the GLP-1 receptor, Tirzepatide on GIP and GLP-1, Retatrutide also on the glucagon receptor. In a head-to-head trial against semaglutide (SURMOUNT-5) weight fell by 20.2 versus 13.7 percent after 72 weeks. A comparison with Retatrutide is still running (TRIUMPH-5, planned end November 2026).

What did the phase 3 trials show?

In SURMOUNT-1 (obesity without diabetes) weight fell by 20.9 percent on average after 72 weeks at the highest study dose, by 3.1 percent on placebo. In SURMOUNT-2 (with type 2 diabetes) it was 14.7 versus 3.2 percent. In SURPASS-1 long-term blood sugar (HbA1c) fell by up to 2.07 percentage points in 40 weeks, on placebo it rose slightly.

How long does Tirzepatide stay in the body?

The half-life in the first human study was about five days (116.7 hours on average). A fatty acid attached to the molecule makes this possible: it lets the molecule bind to the blood protein albumin. That fits one dose a week, which is how the trials give it.

What happens after stopping?

SURMOUNT-4 tested this. After 36 weeks of Tirzepatide everyone had lost 20.9 percent on average. Those switched to placebo regained 14.0 percent on average by week 88. Those who continued lost a further 5.5 percent. Over the whole period it was 25.3 versus 9.9 percent.

Which side effects were seen?

Most often gastrointestinal effects such as nausea, diarrhoea and vomiting, mostly mild to moderate and mainly while the dose was being increased. In SURMOUNT-1 4.3 to 7.1 percent stopped because of side effects depending on the dose, 2.6 percent on placebo. A phase 2 trial showed that a lower start and smaller steps went along with fewer complaints.

What is known about heart, liver and sleep apnoea?

In SUMMIT (heart failure with preserved ejection fraction and obesity) 9.9 percent had cardiovascular death or worsening heart failure, 15.3 percent on placebo. In SURPASS-CVOT Tirzepatide was not worse than dulaglutide for cardiovascular events. In SYNERGY-NASH MASH resolved in 62 percent at the highest study dose, in 10 percent on placebo. In sleep apnoea the number of breathing pauses per hour fell by 25.3 in one of the two trials, by 5.3 on placebo.

Which trials are still running?

Six of the listed phase 3 trials are not finished yet. The largest is SURMOUNT-MMO on morbidity and mortality in obesity with 15,374 participants (planned end October 2027). There are also trials in type 1 diabetes, in adolescents and in children aged 6 to 11.

Usporedbe

Kako se uspoređuje

Povezano

Srodni proizvodi